Randomized, open-label study of oral ABL001 versus bosutinib in patients with Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in chronic phase, previously treated with 2 or more tyrosine kinase inhibitors
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) versus IV Decitabine in Subjects with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery
DIARRHEA PREVENTION AND PROPHYLAXIS WITH CROFELEMER IN HER2 POSITIVE BREAST CANCER PATIENTS RECEIVING TRASTUZUMAB, PERTUZUMAB, AND DOCETAXEL OR PACLITAXEL WITH OR WITHOUT CARBOPLATIN
A Multicenter Phase 2 Study of the Glutaminase Inhibitor CB-839 in Combination with Paclitaxel in Patients with Advanced Triple Negative Breast Cancer (TNBC) Including Patients of African Ancestry and Non-African Ancestry
Phase 1b/2, Open Label, study of Alcalabrutinib alone or in combination with Rituximab in subjects with Indolent B-Cell, Non-Hodgkins Lymphoma (MZL)
A Phase 2, Open Label, 2-Cohort, Multi-center Study of INCB50465, a P13K Inhibitor, in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated with or Without a BTK Inhibitor
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
An Open-Label Phase ½ Study of INCB039110 in Combination With Ibrutinib in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
